DURECT is a specialty pharmaceutical company focused on developing innovative drugs for pain and chronic diseases, with late-stage development programs including REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil. The company’s proprietary oral, transdermal and injectable depot delivery technologies facilitate new indications and superior clinical/commercial attributes, including abuse deterrence and improved convenience, compliance, efficacy and safety for small molecule and biologic drugs. For more information, visit the company’s Web site at www.durect.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: